Literature DB >> 23115180

A novel BACHD transgenic rat exhibits characteristic neuropathological features of Huntington disease.

Libo Yu-Taeger1, Elisabeth Petrasch-Parwez, Alexander P Osmand, Adriana Redensek, Silke Metzger, Laura E Clemens, Larry Park, David Howland, Carsten Calaminus, Xiaofeng Gu, Bernd Pichler, X William Yang, Olaf Riess, Huu Phuc Nguyen.   

Abstract

Huntington disease (HD) is an inherited progressive neurodegenerative disorder, characterized by motor, cognitive, and psychiatric deficits as well as neurodegeneration and brain atrophy beginning in the striatum and the cortex and extending to other subcortical brain regions. The genetic cause is an expansion of the CAG repeat stretch in the HTT gene encoding huntingtin protein (htt). Here, we generated an HD transgenic rat model using a human bacterial artificial chromosome (BAC), which contains the full-length HTT genomic sequence with 97 CAG/CAA repeats and all regulatory elements. BACHD transgenic rats display a robust, early onset and progressive HD-like phenotype including motor deficits and anxiety-related symptoms. In contrast to BAC and yeast artificial chromosome HD mouse models that express full-length mutant huntingtin, BACHD rats do not exhibit an increased body weight. Neuropathologically, the distribution of neuropil aggregates and nuclear accumulation of N-terminal mutant huntingtin in BACHD rats is similar to the observations in human HD brains. Aggregates occur more frequently in the cortex than in the striatum and neuropil aggregates appear earlier than mutant htt accumulation in the nucleus. Furthermore, we found an imbalance in the striatal striosome and matrix compartments in early stages of the disease. In addition, reduced dopamine receptor binding was detectable by in vivo imaging. Our data demonstrate that this transgenic BACHD rat line may be a valuable model for further understanding the disease mechanisms and for preclinical pharmacological studies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23115180      PMCID: PMC6621569          DOI: 10.1523/JNEUROSCI.1148-12.2012

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  35 in total

Review 1.  The chicken or the egg: mitochondrial dysfunction as a cause or consequence of toxicity in Huntington's disease.

Authors:  Aris A Polyzos; Cynthia T McMurray
Journal:  Mech Ageing Dev       Date:  2016-09-12       Impact factor: 5.432

2.  The BACHD Rat Model of Huntington Disease Shows Signs of Fronto-Striatal Dysfunction in Two Operant Conditioning Tests of Short-Term Memory.

Authors:  Erik Karl Håkan Clemensson; Laura Emily Clemensson; Olaf Riess; Huu Phuc Nguyen
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

Review 3.  Mutant Huntingtin and Elusive Defects in Oxidative Metabolism and Mitochondrial Calcium Handling.

Authors:  Nickolay Brustovetsky
Journal:  Mol Neurobiol       Date:  2015-05-05       Impact factor: 5.590

Review 4.  Timing behavior in genetic murine models of neurological and psychiatric diseases.

Authors:  Ayşe Karson; Fuat Balcı
Journal:  Exp Brain Res       Date:  2021-01-06       Impact factor: 1.972

5.  Mitochondrial membrane fluidity is consistently increased in different models of Huntington disease: restorative effects of olesoxime.

Authors:  Janett Eckmann; Laura E Clemens; Schamim H Eckert; Stephanie Hagl; Libo Yu-Taeger; Thierry Bordet; Rebecca M Pruss; Walter E Muller; Kristina Leuner; Huu P Nguyen; Gunter P Eckert
Journal:  Mol Neurobiol       Date:  2014-03-18       Impact factor: 5.590

Review 6.  Choosing an animal model for the study of Huntington's disease.

Authors:  Mahmoud A Pouladi; A Jennifer Morton; Michael R Hayden
Journal:  Nat Rev Neurosci       Date:  2013-10       Impact factor: 34.870

Review 7.  Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.

Authors:  Jana Miniarikova; Melvin M Evers; Pavlina Konstantinova
Journal:  Mol Ther       Date:  2018-02-08       Impact factor: 11.454

8.  Sustained mobilization of endogenous neural progenitors delays disease progression in a transgenic model of Huntington's disease.

Authors:  Abdellatif Benraiss; Michael J Toner; Qiwu Xu; Elodie Bruel-Jungerman; Eloise H Rogers; Fushun Wang; Aris N Economides; Beverly L Davidson; Ryoichiro Kageyama; Maiken Nedergaard; Steven A Goldman
Journal:  Cell Stem Cell       Date:  2013-06-06       Impact factor: 24.633

9.  Motivational Impairment is Accompanied by Corticoaccumbal Dysfunction in the BACHD-Tg5 Rat Model of Huntington's Disease.

Authors:  Natalie E Zlebnik; Iness Gildish; Thibaut Sesia; Aurelie Fitoussi; Ellen A Cole; Brian P Carson; Roger Cachope; Joseph F Cheer
Journal:  Cereb Cortex       Date:  2019-12-17       Impact factor: 5.357

10.  Site-specific ubiquitination of pathogenic huntingtin attenuates its deleterious effects.

Authors:  Vicky Hakim-Eshed; Ayub Boulos; Chen Cohen-Rosenzweig; Libo Yu-Taeger; Tamar Ziv; Yong Tae Kwon; Olaf Riess; Hoa Huu Phuc Nguyen; Noam E Ziv; Aaron Ciechanover
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.